alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 6,026–6,050 of 27,146 studies marked Peer-reviewed (page 242 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Associations of the Mediterranean diet with cognitive and neuroimaging phenotypes of dementia in healthy older adults

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The American journal of clinical nutrition 2019-02-01

When compared with the Low MedDiet group, the High MedDiet group was associated with better L&M performance and larger dentate gyri. 5 key findings →

Design: cross-sectional Participants: 82 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Body Mass Index and Decline in Cognitive Function in Older Black and White Persons

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2018-01-01

Late-life lower BMI relates to faster rates of decline in cognition, specifically semantic memory and episodic memory, in both blacks and whites. 2 key findings →

Design: cohort study Participants: 2,134 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Long-term exposure to air pollution and mortality in a Danish nationwide administrative cohort study: Beyond mortality from cardiopulmonary disease and lung cancer

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Environment international 2022-04-12

Long-term exposure to PM 2.5 , NO 2 , and/or BC in Denmark were associated with mortality beyond cardiorespiratory diseases, including diabetes, dementia, psychiatric disorders, asthma, and ALRI. 5 key findings →

Participants: 803,881 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive screening tools for identification of dementia in illiterate and low-educated older adults, a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 57 out of 100. International psychogeriatrics 2017-03-09

Numerous tools for assessment of cognitive impairment in low-literacy settings have been developed, and tools developed for use in high-income countries have also been validated in low-literacy settings. 2 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The impact of family caregivers on potentially inappropriate medication use in noninstitutionalized older adults with dementia

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The American journal of geriatric pharmacotherapy 2012-06-09

PIM use may be higher in dementia patients and their informal caregivers compared with the general older adult population. 5 key findings →

Participants: 566 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Relationship between Residential Segregation, Later-Life Cognition, and Incident Dementia across Race/Ethnicity

✓ Peer-reviewed alzhub usefulness score 57 out of 100. International journal of environmental research and public health 2021-10-26

Systemic racism leads to racial/ethnic residential segregation, which can result in health inequities. 3 key findings →

Participants: 4,616 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cardiovascular death in rheumatoid arthritis: a population-based study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Arthritis and rheumatism 2005-03-01

These results indicate that markers of systemic inflammation confer a statistically significant additional risk for cardiovascular death among patients with RA, even after controlling for traditional cardiovascular risk factors and comorbidities. 3 key findings →

Participants: 354 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

2009 Alzheimer's disease facts and figures

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2009-05-01

Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States, and the fifth leading cause of death in Americans aged 65 and older. 1 key finding →

Participants: 200,000 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 2007-03-01

The plasma Abeta42/Abeta40 ratio may be a useful premorbid biomarker for identifying cognitively normal elderly white subjects who are at increased risk for developing MCI or AD. 5 key findings →

Participants: 53 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-01-01

Declines in heart disease and stroke mortality rates are conventionally attributed to reductions in cigarette smoking, recognition and treatment of hypertension and diabetes, effective medications to improve serum lipid levels and to reduce clot formation, and general lifestyle improvements. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

What the left and right anterior fusiform gyri tell us about semantic memory

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Brain : a journal of neurology 2010-10-15

The study of patients with semantic dementia, a variant of frontotemporal lobar degeneration, has emerged over the last two decades as an important lesion model for studying human semantic memory. 4 key findings →

Participants: 21 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Estrogen replacement therapy and risk of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of internal medicine 1996-10-01

This study suggests that estrogen replacement therapy may be useful for preventing or delaying the onset of Alzheimer disease in postmenopausal women. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The natural history of dementia in Down's syndrome

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 1990-03-01

In a prospective longitudinal study with death as the end point in 17 middle-aged patients with Down's syndrome, dementia was clinically diagnosed in 15 patients, by means of careful observations in daily circumstances. 2 key findings →

Design: longitudinal study Participants: 15 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A randomized controlled trial of the effects of multi-sensory stimulation (MSS) for people with dementia

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The British journal of clinical psychology 2001-03-01

Both MSS and Activity sessions appear to be effective and appropriate therapies for people with dementia. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed